Royce & Associates LP Buys Shares of 533,300 CeriBell, Inc. $CBLL

Royce & Associates LP bought a new stake in CeriBell, Inc. (NASDAQ:CBLL) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 533,300 shares of the company’s stock, valued at approximately $11,695,000. Royce & Associates LP owned about 1.44% of CeriBell as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. CWM LLC lifted its stake in CeriBell by 1,178.5% in the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after acquiring an additional 1,697 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in CeriBell by 353.8% in the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after acquiring an additional 1,801 shares during the last quarter. Larson Financial Group LLC raised its position in shares of CeriBell by 1,403.1% in the fourth quarter. Larson Financial Group LLC now owns 2,871 shares of the company’s stock valued at $63,000 after purchasing an additional 2,680 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of CeriBell in the third quarter valued at approximately $33,000. Finally, SG Americas Securities LLC bought a new position in shares of CeriBell in the fourth quarter valued at approximately $145,000.

Analysts Set New Price Targets

A number of research firms have recently commented on CBLL. BTIG Research reissued a “buy” rating and issued a $30.00 price target on shares of CeriBell in a research report on Wednesday, January 28th. Weiss Ratings lowered shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, May 12th. Finally, Canaccord Genuity Group dropped their price target on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $22.20.

Insider Buying and Selling

In related news, VP David Foehr sold 4,560 shares of the company’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $17.80, for a total transaction of $81,168.00. Following the transaction, the vice president owned 17,550 shares in the company, valued at $312,390. This represents a 20.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CTO Raymond Woo sold 11,112 shares of the company’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $18.56, for a total transaction of $206,238.72. Following the transaction, the chief technology officer owned 166,912 shares in the company, valued at approximately $3,097,886.72. This trade represents a 6.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 165,300 shares of company stock worth $3,086,400 in the last 90 days. Corporate insiders own 20.10% of the company’s stock.

CeriBell Stock Down 0.5%

Shares of NASDAQ:CBLL opened at $18.70 on Thursday. The company’s fifty day moving average is $19.08 and its 200-day moving average is $19.29. The company has a market capitalization of $709.48 million, a PE ratio of -11.47 and a beta of 0.99. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.01 and a current ratio of 10.44. CeriBell, Inc. has a 52 week low of $10.85 and a 52 week high of $24.33.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.13). The company had revenue of $26.49 million for the quarter, compared to analyst estimates of $26.09 million. CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%. Equities research analysts predict that CeriBell, Inc. will post -1.69 earnings per share for the current fiscal year.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.